23andMe Stock

23andme.com | Healthcare/Biotech | Founded: 2006 | Funding to Date: $791,607,056

23andMe was founded on April 1, 2006 by Anne Wojcicki and Linda Avery. The company offers consumer genetic testing as well as supports genetic research. The consumer genetics and research platform give customers interactive, web-based access to their genetic profile. They regularly increase the capabilities of the platform giving users more insight into their DNA. 23andMe was named by MIT Technology Review to its “50 Smartest Companies, 2017” List, and named one of Fast Company’s “25 Brands That Matter Now, 2017”. According to the company, 23andMe has millions of customers worldwide, and approximately 85% consented to participate in research. 23andMe is located in Mountain View, CA. As of December 2018.

ENTERPRISE VALUE (based on primary fundings)

Key Investors
Fidelity Investments
Casdin Capital
Altimeter Capital
Sequoia Capital

Learn more about a potential 23andMe IPO >>

TEAM

Management Team
  • Anne Wojcicki - CEO & Co-Founder
  • Dean Schorno - CFO & Head of Operations
  • Kathy Hibbs JD - Chief Legal & Regulatory Officer
  • Richard Scheller Ph.D - Chief Scientific Officer & Head of Therapeutics
  • Mike Polcari - Vice President & Chief Architect
Board Members
  • Anne Wojcicki - 23andMe
  • Esther Dyson - Self
  • Nicholas Naclerio Ph.D - Illumina
  • Patrick Chung JD - Xfund
  • Neal Mohan - 23andMe
  • Roelof Botha - Sequoia Capital

NEWS

Tech Times

Separating fact from fiction in the home DNA testing industry. In recent years, consumer DNA testing kit services have exploded in popularity. The MIT Technology Review called 2017 the "year consumer DNA testing blew up" as it was the first time more people had their DNA tested in a single year than all previous years combined.

Politico

New push for AI in radiology — 23andMe responds to study on BRCA misses

Token Index
Private Growth Index
To view this content, please sign up or login.

Sign Up  Log In

Close